Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Clinical and Pharmacokinetic Study of Zalypsis in Platinum-pretreated Advanced or Metastatic Urothelial Carcinoma
2010-020994-18Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Jul 2010
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zalypsis in transitional cell carcinoma (TCC), sponsored by PharmaMar. Primary endpoint: Tumor Control Rate (TCT). Started Jul 2010; status: completed.
02
Drugs
zalypsis
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2010-020994-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020994-18.